AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Zip code for 4d molecular therapeutics11/10/2023 Here we report first-time interim results from the dose exploration portion of the Phase 1/2 PRISM study evaluating the safety and activity of 4D-150 in individuals with neovascular (wet) age-related macular degeneration (wAMD) who require frequent anti-VEGF therapy. Commercial Relationships Arshad Khanani Abbvie, Adverum Biotechnologies, AGTC, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Arrowhead, Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch & Lomb, BroadWing Bio, Cholgene Therapeutics, 4D Molecular Therapeutics, Eyepoint Pharmaceuticals, Fronterra Therapeutics, Gemini Pharmaceuticals, Genentech, Graybug Vision, Gyroscope Therapeutics, Iveric Bio, Janssen Pharmaceuticals, Kato Pharmaceuticals, Kartos Therapeutics, Kodiak Sciences, Kriya Therapeutics, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Novartis, Perfuse, PolyPhotonix, Ray Therapeutics, Recens Medical, Regeneron Pharmaceuticals, REGENXBIO, Roche, Stealth Biotherapeutics Therapeutics, Thea Pharma, UNITY Biotechnology, Vanotech, Code C (Consultant/Contractor), Adverum Biotechnologies, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, 4D Molecular Therapeutics, Gemini Pharmaceuticals, Genentech, Graybug Vision, Gyroscope Therapeutics, Iveric Bio, Janssen Pharmaceuticals, Kodiak, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Recens Medical, REGENXBIO, Roche, UNITY Biotechnology, Code F (Financial Support), Abbvie, Apellis, Aviceda Therapeutics, Genentech, Novartis, PolyPhotonix, Recens Medical, Code R (Recipient) Vrinda Hershberger None Christine Kay 4D Molecular Therapeutics, Atsena Therapeutics, Biogen, Janssen, Kiora, Code C (Consultant/Contractor), 4D Molecular Therapeutics, AGTC, Alkeus, Biogen, FFB, Iveric Bio Meira/Janssen, ProQR, Code F (Financial Support) Allen Hu None David Eichenbaum Genentech, Regeneron, Allergan, Novartis, Alimera, Opthea, US Retina, EyePoint, Gyroscope, Kodiak, RecensMedical, DORC, Iveric Bio, Apellis, KKR, Regenxbio, Bausch & Lomb, Vial, Coherus, Outlook, Crinetics, ReVive, Code C (Consultant/Contractor), Clearside, US Retina, Hemera Biopharmaceuticals, Boston Image Reading Center, Network Eye, Outlook, Revive, Code E (Employment), 4D Molecular Therapeutics, Genentech, Regeneron, Bayer, Novartis, Opthea, Ocular Therapeutix, EyePoint, Mylan, Chengdu, Gemini, Gyroscope, Kodiak, NGM, RecensMedical, Alkahest, Ionis, Iveric Bio, Regenxbio, Unity, Annexon, Alexion, Code F (Financial Support), Network Eye, Code O (Owner), Genentech, Allergan, Novartis, EyePoint, DORC, Apellis, Bausch & Lomb, Code R (Recipient) Glenn Jaffe 4D Molecular Therapeutics, Novartis, Roche/Genentech, Eyepoint pharmaceuticals, Code C (Consultant/Contractor) Carol Chung 4D Molecular Therapeutics, Code C (Consultant/Contractor) Somayeh Honarmand 4D Molecular Therapeutics, Code E (Employment) Chyong Nien 4D Molecular Therapeutics, Code E (Employment) Schonmei Lee 4D Molecular Therapeutics, Code E (Employment) Harsha Kabra 4D Molecular Therapeutics, Code E (Employment) David Kirn 4D Molecular Therapeutics, Code O (Owner) Robert Kim 4D Molecular Therapeutics, Code E (Employment)ĤD-150 is a single-dose intravitreal (IVT) retinotropic AAV vector (R100) carrying two transgenes encoding aflibercept (AFLB) and an miRNA sequence targeting VEGF-C.
0 Comments
Read More
Leave a Reply. |